India, May 28 -- Candel Therapeutics, Inc. (CADL) shares rose 4.55 percent to $5.85 on Wednesday, gaining $0.26, after the company announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its lead candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in intermediate-to-high-risk patients. Candel opened at $5.66 and traded between $5.66 and $6.29 on the Nasdaq. Volume reached 1.43 million shares, surpassing its average of 976,245. The stock previously closed at $5.60 and has a 52-week range of $3.79 to $14.60.
The therapy had previously received Fast Track designation for the same indication. CAN-2409 is a biological immunotherapy designed to activate th...